The coronavirus pandemic wiped billions from global drug stock valuations in the first quarter, with the few gainers failing to offset huge losses elsewhere.
As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…
As Cepi asks for $2bn to fund development of a vaccine against coronavirus and Moderna moves into the clinic, Vantage takes a look at previous pandemic development costs.
The US regulator granted 14 accelerated approvals in 2019, fewer than in the previous two years, and the sector remains slow at conversions.
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.
Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
A clutch of swift FDA decisions boosted average US drug approval times in 2019, helping biopharma to deliver another bumper crop of new medicines.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…